Society Letters

Endocrine Society NIOSH Hazardous Drug List Comments

June 25, 2020

To: John Howard, MD, MPH, JD, LLM, MBA, NIOSH Docket Office

"We support the intent behind NIOSH’s Hazardous Drug List of keeping workers safe from unnecessary harm, but do not believe that available evidence points to a need for the inclusion of liraglutide. Therefore, we respectfully ask that you remove the drug from the list. "

arrowRead the Full Summary

Last Updated:
Take Action

Make Your Voice Heard

Take Action
We rely on your voice to advocate for our policy priorities. Join us to show our strength as a community that cares about endocrinology. Contact your U.S representatives or European Members of Parliament through our online platform. Take action and make a difference today.

We rely on your voice to advocate for our policy priorities. Join us to show our strength as a community that cares about endocrinology. Contact your U.S representatives or European Members of Parliament through our online platform. Take action and make a difference today.

Back to top

Who We Are

For 100 years, the Endocrine Society has been at the forefront of hormone science and public health. Read about our history and how we continue to serve the endocrine community.